MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12904-025-01687-5

Медицинская библиотека · BMC palliative care · 2025

Emergency palliative cancer care: anxiety and midazolam.

Tranung Morten, Solheim Tora S, Løhre Erik Torbjørn, Thronaes Morten, Larsen Michael Due

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

Cancer patients treated with palliative intent often report anxiety. Anxiety is associated with dyspnoea, cancer pain, and reduced quality of life. Limited knowledge on variability and treatment effects warranted exploring factors associated with improvement in anxiety for hospitalised palliative cancer patients.

METHODS

This study is a cross-sectional secondary analysis. All patients admitted to an acute palliative care unit for one year were assessed and 164 patients satisfied the study inclusion criteria. The patients reported self-registered symptom intensities using the 11-point numeric rating scale. Demographic variables, patient reports, and medical management were analysed for associations with anxiety.

RESULTS

At admission, 37.8% of the patients reported moderate or severe anxiety, and of these 43.6% used benzodiazepines. The corresponding numbers for benzodiazepine use were 35.1% and 24.4% for patients with mild and no anxiety, respectively. Of all patients, 26.8% reported improved anxiety during their hospital stay. More patients with moderate or severe anxiety at admission reported improved anxiety during hospitalisation (50.0%) compared to the corresponding patients with mild anxiety (22.8%). Patients with moderate or severe anxiety reported less improvement in pain compared to patients with mild anxiety. Improved dyspnoea was the only factor statistically associated with improvement in anxiety, both for patients reporting mild anxiety and moderate and severe anxiety. Thirty-seven-point-1% of patients with moderate or severe anxiety at admission received no benzodiazepine treatment during the hospital stay. Patients receiving midazolam had more anxiety at admission, were younger, and had poorer performance status. Median dose and interquartile range [IQR] of midazolam in these patients were 2 mg/24 h [IQR: 2.0-6.0].

CONCLUSION

Improved dyspnoea was associated with reduced anxiety; however, the use of benzodiazepines was not.

Для цитирования: Tranung Morten, Solheim Tora S, Løhre Erik Torbjørn, Thronaes Morten, Larsen Michael Due. Emergency palliative cancer care: anxiety and midazolam.. BMC palliative care. 2025. DOI: 10.1186/s12904-025-01687-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.